PARIS--The luteinizing hormone-releasing hormone (LHRH) agonist
goserelin (Zoladex) proved as effective as surgical ovariectomy
in premenopausal women with estrogen and/or progestogen receptor-positive
metastatic breast cancer, a randomized multicenter study has shown.
Investigator Charles W. Taylor of the University of Arizona, Tucson,
presented the results of the study, SWOG 8692, at the Sixth International
Congress on Anti-Cancer Treatment. The trial was conducted by
investigators from the Southwestern Oncology Group, North Central
Cancer Treatment Group, and Eastern Cooperative Oncology Group.
The 135 participants in this study were assigned to undergo either
surgical ovariectomy or treatment with monthly subcutaneous injections
of goserelin, 3.6 mg. None had undergone previous chemotherapy
or hormonal therapy, except in the adjuvant setting, and none
had brain metastases or life-threatening lung or liver metastases.
Dr. Taylor reported that both failure-free and overall survival
were equivalent with the two modes of ovarian ablation. The time
to treatment failure averaged 3 months in surgically treated patients
and 6 months in the goserelin group; median overall survival rates
were 33 months and 35 months, respectively. Rates of objective
tumor regression were similarly low in both treatment groups.